Format

Send to

Choose Destination
J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009. Epub 2016 Jul 9.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Author information

1
Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
2
Rush University Medical Center, Chicago, Illinois.
3
University of Colorado Cancer Center, Denver, Colorado.
4
Memorial Sloan Kettering Cancer Center, New York, New York.
5
The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
6
U.S. Food and Drug Administration, Silver Spring, Maryland.
7
Oregon Health and Science University, Portland, Oregon.
8
National Cancer Institute, Bethesda, Maryland.
9
Vanderbilt University Medical Center, Nashville, Tennessee.
10
LUNGevity Foundation, Bethesda, Maryland.
11
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
12
Dana Farber Cancer Institute, Boston, Massachusetts.
13
The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
14
Yale School of Medicine, New Haven, Connecticut.
15
U.S. Food and Drug Administration, Silver Spring, Maryland. Electronic address: Gideon.Blumenthal@fda.hhs.gov.

Abstract

Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.

KEYWORDS:

Clinical trials; Immunotherapy; Lung cancer; Targeted therapy

PMID:
27401214
PMCID:
PMC5131641
DOI:
10.1016/j.jtho.2016.05.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center